PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT
First Claim
Patent Images
1. A controlled release oral dosage form comprising:
- a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients;
said dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid;
said dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
-
Citations
21 Claims
-
1. A controlled release oral dosage form comprising:
-
a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; said dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; said dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
-
21-40. -40. (canceled)
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneePurdue Pharma L.P.
-
Original AssigneePurdue Pharma L.P.
-
InventorsWright, Curtis, Oshlack, Benjamin, Breder, Christopher
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/282
-
CPC Class CodesA61J 3/10 into the form of compressed...A61K 31/137 Arylalkylamines, e.g. amphe...A61K 31/167 having the nitrogen of a ca...A61K 31/192 having aromatic groups, e.g...A61K 31/439 the ring forming part of a ...A61K 31/4458 only substituted in positio...A61K 31/48 Ergoline derivatives, e.g. ...A61K 31/485 Morphinan derivatives, e.g....A61K 45/06 Mixtures of active ingredie...A61K 47/02 Inorganic compoundsA61K 47/08 containing oxygen, e.g. eth...A61K 47/10 Alcohols; Phenols; Salts th...A61K 47/12 Carboxylic acids; Salts or ...A61K 47/14 Esters of carboxylic acids,...A61K 47/20 containing sulfur, e.g. dim...A61K 47/26 Carbohydrates, e.g. sugar a...A61K 47/32 Macromolecular compounds ob...A61K 47/34 Macromolecular compounds ob...A61K 47/36 Polysaccharides; Derivative...A61K 47/38 Cellulose; Derivatives thereofView All
